Edwards Lifesciences Corporation (EW)
USD 72.81
(-1.77%)
USD 72.81
(-1.77%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 1.4 Billion USD | -7.85% |
| 2022 | 1.52 Billion USD | 1.25% |
| 2021 | 1.5 Billion USD | 82.55% |
| 2020 | 823.4 Million USD | -21.35% |
| 2019 | 1.04 Billion USD | 44.96% |
| 2018 | 722.2 Million USD | 16.09% |
| 2017 | 622.1 Million USD | 9.24% |
| 2016 | 569.5 Million USD | 15.07% |
| 2015 | 494.9 Million USD | -38.98% |
| 2014 | 811.1 Million USD | 107.07% |
| 2013 | 391.7 Million USD | 33.59% |
| 2012 | 293.2 Million USD | 23.87% |
| 2011 | 236.7 Million USD | 8.58% |
| 2010 | 218 Million USD | -4.85% |
| 2009 | 229.1 Million USD | 77.73% |
| 2008 | 128.9 Million USD | 14.07% |
| 2007 | 113 Million USD | -13.41% |
| 2006 | 130.5 Million USD | 64.56% |
| 2005 | 79.3 Million USD | 4564.71% |
| 2004 | 1.7 Million USD | -97.85% |
| 2003 | 79 Million USD | 41.83% |
| 2002 | 55.7 Million USD | 564.17% |
| 2001 | -12 Million USD | 95.59% |
| 2000 | -272 Million USD | -431.71% |
| 1999 | 82 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 351.9 Million USD | -4.87% |
| 2024 Q3 | 3.07 Billion USD | 738.33% |
| 2024 Q2 | 366.3 Million USD | 4.09% |
| 2023 Q3 | 384.9 Million USD | 25.33% |
| 2023 Q4 | 369.9 Million USD | -3.9% |
| 2023 FY | 1.4 Billion USD | -7.85% |
| 2023 Q1 | 340.5 Million USD | -14.53% |
| 2023 Q2 | 307.1 Million USD | -9.81% |
| 2022 Q1 | 373.6 Million USD | 11.42% |
| 2022 FY | 1.52 Billion USD | 1.25% |
| 2022 Q3 | 343.5 Million USD | -15.48% |
| 2022 Q2 | 406.4 Million USD | 8.78% |
| 2022 Q4 | 398.4 Million USD | 15.98% |
| 2021 FY | 1.5 Billion USD | 82.55% |
| 2021 Q1 | 338.2 Million USD | 9.27% |
| 2021 Q3 | 340.1 Million USD | -30.52% |
| 2021 Q2 | 489.5 Million USD | 44.74% |
| 2021 Q4 | 335.3 Million USD | -1.41% |
| 2020 Q2 | -121.9 Million USD | -139.25% |
| 2020 Q1 | 310.6 Million USD | 10.85% |
| 2020 Q4 | 309.5 Million USD | -4.83% |
| 2020 Q3 | 325.2 Million USD | 366.78% |
| 2020 FY | 823.4 Million USD | -21.35% |
| 2019 Q4 | 280.2 Million USD | 2.0% |
| 2019 Q1 | 249.7 Million USD | 3467.14% |
| 2019 Q2 | 242.3 Million USD | -2.96% |
| 2019 Q3 | 274.7 Million USD | 13.37% |
| 2019 FY | 1.04 Billion USD | 44.96% |
| 2018 Q3 | 225.9 Million USD | -20.09% |
| 2018 FY | 722.2 Million USD | 16.09% |
| 2018 Q2 | 282.7 Million USD | 36.83% |
| 2018 Q1 | 206.6 Million USD | 478.71% |
| 2018 Q4 | 7 Million USD | -96.9% |
| 2017 Q1 | 230.2 Million USD | 45.24% |
| 2017 FY | 622.1 Million USD | 9.24% |
| 2017 Q4 | 35.7 Million USD | -79.01% |
| 2017 Q2 | 186.1 Million USD | -19.16% |
| 2017 Q3 | 170.1 Million USD | -8.6% |
| 2016 Q3 | 141.4 Million USD | 11.69% |
| 2016 Q2 | 126.6 Million USD | -11.47% |
| 2016 Q4 | 158.5 Million USD | 12.09% |
| 2016 Q1 | 143 Million USD | 1.63% |
| 2016 FY | 569.5 Million USD | 15.07% |
| 2015 FY | 494.9 Million USD | -38.98% |
| 2015 Q4 | 140.7 Million USD | 19.14% |
| 2015 Q2 | 112.7 Million USD | -8.67% |
| 2015 Q3 | 118.1 Million USD | 4.79% |
| 2015 Q1 | 123.4 Million USD | 13.0% |
| 2014 Q4 | 109.2 Million USD | 15.43% |
| 2014 Q3 | 94.6 Million USD | -82.71% |
| 2014 FY | 811.1 Million USD | 107.07% |
| 2014 Q2 | 547 Million USD | 807.13% |
| 2014 Q1 | 60.3 Million USD | -20.45% |
| 2013 Q2 | 93.3 Million USD | -35.16% |
| 2013 FY | 391.7 Million USD | 33.59% |
| 2013 Q4 | 75.8 Million USD | -1.3% |
| 2013 Q3 | 76.8 Million USD | -17.68% |
| 2013 Q1 | 143.9 Million USD | 57.96% |
| 2012 Q2 | 67.8 Million USD | 4.15% |
| 2012 Q1 | 65.1 Million USD | 3.17% |
| 2012 Q3 | 69.2 Million USD | 2.06% |
| 2012 FY | 293.2 Million USD | 23.87% |
| 2012 Q4 | 91.1 Million USD | 31.65% |
| 2011 Q3 | 51.6 Million USD | -11.19% |
| 2011 Q4 | 63.1 Million USD | 22.29% |
| 2011 Q1 | 63.9 Million USD | -1.39% |
| 2011 FY | 236.7 Million USD | 8.58% |
| 2011 Q2 | 58.1 Million USD | -9.08% |
| 2010 Q4 | 64.8 Million USD | 35.0% |
| 2010 FY | 218 Million USD | -4.85% |
| 2010 Q1 | 47.7 Million USD | 0.21% |
| 2010 Q2 | 57.5 Million USD | 20.55% |
| 2010 Q3 | 48 Million USD | -16.52% |
| 2009 FY | 229.1 Million USD | 77.73% |
| 2009 Q4 | 47.6 Million USD | -35.24% |
| 2009 Q3 | 73.5 Million USD | 54.74% |
| 2009 Q2 | 47.5 Million USD | -21.49% |
| 2009 Q1 | 60.5 Million USD | 58.79% |
| 2008 Q2 | 39.7 Million USD | 118.13% |
| 2008 FY | 128.9 Million USD | 14.07% |
| 2008 Q4 | 38.1 Million USD | 15.81% |
| 2008 Q3 | 32.9 Million USD | -17.13% |
| 2008 Q1 | 18.2 Million USD | 15.19% |
| 2007 Q2 | 34.9 Million USD | 5.12% |
| 2007 Q3 | 29.1 Million USD | -16.62% |
| 2007 Q1 | 33.2 Million USD | 60.39% |
| 2007 Q4 | 15.8 Million USD | -45.7% |
| 2007 FY | 113 Million USD | -13.41% |
| 2006 Q1 | 46 Million USD | 19.17% |
| 2006 Q2 | 36.1 Million USD | -21.52% |
| 2006 FY | 130.5 Million USD | 64.56% |
| 2006 Q3 | 27.8 Million USD | -22.99% |
| 2006 Q4 | 20.7 Million USD | -25.54% |
| 2005 Q4 | 38.6 Million USD | 977.27% |
| 2005 Q1 | 31.2 Million USD | 20.46% |
| 2005 Q2 | 13.9 Million USD | -55.45% |
| 2005 Q3 | -4.4 Million USD | -131.65% |
| 2005 FY | 79.3 Million USD | 4564.71% |
| 2004 Q2 | 25.5 Million USD | 141.06% |
| 2004 FY | 1.7 Million USD | -97.85% |
| 2004 Q4 | 25.9 Million USD | 108.87% |
| 2004 Q3 | 12.4 Million USD | -51.37% |
| 2004 Q1 | -62.1 Million USD | -428.57% |
| 2003 Q4 | 18.9 Million USD | -22.86% |
| 2003 Q1 | 14.5 Million USD | -33.18% |
| 2003 Q2 | 21.1 Million USD | 45.52% |
| 2003 Q3 | 24.5 Million USD | 16.11% |
| 2003 FY | 79 Million USD | 41.83% |
| 2002 FY | 55.7 Million USD | 564.17% |
| 2002 Q2 | 30.6 Million USD | 47.12% |
| 2002 Q4 | 21.7 Million USD | 224.71% |
| 2002 Q3 | -17.4 Million USD | -156.86% |
| 2002 Q1 | 20.8 Million USD | 26.06% |
| 2001 Q2 | -55.7 Million USD | -538.58% |
| 2001 Q3 | 14.5 Million USD | 126.03% |
| 2001 FY | -12 Million USD | 95.59% |
| 2001 Q4 | 16.5 Million USD | 13.79% |
| 2001 Q1 | 12.7 Million USD | -48.79% |
| 2000 FY | -272 Million USD | -431.71% |
| 2000 Q1 | 17 Million USD | -15.0% |
| 2000 Q2 | -309 Million USD | -1917.65% |
| 2000 Q3 | 4.4 Million USD | 101.42% |
| 2000 Q4 | 24.8 Million USD | 463.64% |
| 1999 FY | 82 Million USD | 0.0% |
| 1999 Q4 | 20 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Abbott Laboratories | 5.72 Billion USD | 75.495% |
| Allurion Technologies Inc. | -82.3 Million USD | 1803.927% |
| Artivion, Inc. | -30.69 Million USD | 4669.567% |
| Avanos Medical, Inc. | -61.8 Million USD | 2369.256% |
| Butterfly Network, Inc. | -133.69 Million USD | 1148.915% |
| Butterfly Network, Inc. | -133.69 Million USD | 1148.915% |
| Bio-Rad Laboratories, Inc. | -637.32 Million USD | 320.045% |
| Boston Scientific Corporation | 1.59 Billion USD | 11.965% |
| Perspective Therapeutics, Inc. | -14.67 Million USD | 9659.646% |
| CONMED Corporation | 64.45 Million USD | -2075.647% |
| Paragon 28, Inc. | -47.84 Million USD | 3031.377% |
| Glaukos Corporation | -134.66 Million USD | 1141.43% |
| Globus Medical, Inc. | 122.87 Million USD | -1041.341% |
| Inspire Medical Systems, Inc. | -21.15 Million USD | 6729.792% |
| Integer Holdings Corporation | 90.65 Million USD | -1447.049% |
| Medtronic plc | 3.67 Billion USD | 61.85% |
| Nevro Corp. | -92.21 Million USD | 1620.827% |
| Owlet, Inc. | -32.9 Million USD | 4362.484% |
| Penumbra, Inc. | 90.95 Million USD | -1441.878% |
| Vicarious Surgical Inc. | -71.07 Million USD | 2073.238% |
| Smith & Nephew plc | 263 Million USD | -433.232% |
| Sonendo, Inc. | -60.91 Million USD | 2402.073% |
| STERIS plc | 378.23 Million USD | -270.771% |
| Stryker Corporation | 3.16 Billion USD | 55.69% |
| Vapotherm, Inc. | -58.19 Million USD | 2509.912% |
| Zimmer Biomet Holdings, Inc. | 1.02 Billion USD | -36.953% |